300. IgG4-related disease Clinical trials / Disease details
Clinical trials : 40 / Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2071210001 | 18/08/2021 | 01/04/2021 | A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease | A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease - VIB0551.P3.S2 | IgG4-Related Disease | RCP: Blinded treatment on Day 1, Day 15, and Week 26: - Inebilizumab group: Inebilizumab 300 mg intravenous (IV) - Placebo group: IV placebo Both groups: Oral prednisone (or equivalent) tablets from Day 1 to the end of Week 8 (tapering dose regimen: 2 weeks each at 20, 15, 10, and 5 mg/day of prednisone or equivalent, open-label, from commercial supply). Optional OLP: Open-label inebilizumab 300 mg IV on Day 1 and Week 26; blinded inebilizumab 300 mg or matching placebo on Day 15, depending on RCP treatment. | Katayama Sota | NULL | Recruiting | >= 20age old | Not applicable | Both | 16 | Phase 3 | USA;China;Australia;Canada;France;Italy;Germay;Hong Kong;Hungary;Israel;Ireland;Mexico;Netherlands;Poland;Argentina;Spain;UK;Turkey;Ukraine;Sweden;India;Japan |
| 2 | NCT04660565 (ClinicalTrials.gov) | January 2021 | 23/9/2020 | Belimumab Treatment for IgG4-related Disease | Belimumab Treatment for IgG4-related Disease, a Prospective, Open-label Clinical Trial | IgG4-related Disease | Drug: Prednisone and Belimumab;Drug: Prednisone | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 75 Years | All | 60 | Phase 4 | China |
| 3 | EUCTR2020-000417-33-IT (EUCTR) | 16/12/2020 | 21/10/2020 | Inebilizumab efficacy and safety in IgG4 related disease | A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4 Related Disease(short title: MITIGATE – InebilizuMab effIcacy and safeTy in IGg4 relATed disEase) - MITIGATE | Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077271;Term: Immunoglobulin G4 related disease;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Inebilizumab Product Code: [Inebilizumab] INN or Proposed INN: Inebilizumab Other descriptive name: afucosylated IgG1 kappa monoclonal antibody Trade Name: PREDNISONE DOC GENERICI - 5 MG COMPRESSE 30 COMPRESSE IN BLISTER PVC-PVDC/ALU Product Name: Prednisone Product Code: [Prednisone] INN or Proposed INN: PREDNISONE Trade Name: CETIRIZINA SANDOZ - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE IN BLISTER PVC/ALU Product Name: Cetirizina Product Code: [Cetirizina] INN or Proposed INN: CETIRIZINA Trade Name: PARACETAMOLO NOVA ARGENTIA - 500 MG COMPRESSE 20 COMPRESSE Product Name: Paracetamolo Product Code: [Paracetamolo] INN or Proposed INN: PARACETAMOLO Trade Name: METILPREDNISOLONE HIKMA - 1000 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONCINI IN VETRO Product Name: Metilprednisolone Product Code: [Metilprednisolone] INN or Proposed INN: METILPREDNISOLONE | VIELABIO Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 3 | United States;Spain;Ukraine;Israel;United Kingdom;Italy;India;France;Hungary;Mexico;Canada;Poland;Australia;Germany;Netherlands;China;Japan;Sweden;Korea, Republic of | ||
| 4 | NCT02703194 (ClinicalTrials.gov) | March 2016 | 27/2/2016 | Leflunomide for Maintenance of Remission in IgG4 Related Disease | A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease | Immunoglobulin G4 Related Sclerosing Disease | Drug: Prednisone;Drug: Leflunomide | Chinese PLA General Hospital | NULL | Completed | 18 Years | 80 Years | All | 68 | Phase 4 | China |
| 5 | NCT02458196 (ClinicalTrials.gov) | April 2015 | 15/4/2015 | Study of Treatment Response on IgG4 Related Disease (IgG4RD) | A Randomized Trial of Treatment in Patients With IgG4-Related Disease | Autoimmune Disease | Drug: Prednisone;Drug: Prednisone and Mycophenolate mofetil | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | China |
| 6 | NCT01758393 (ClinicalTrials.gov) | December 2012 | 24/12/2012 | Glucocorticoids in Patients With IgG4-RD | A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease | IgG4-related Disease | Drug: Prednisone | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 70 Years | Both | 40 | Phase 2/Phase 3 | China |